These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24319174)

  • 21. Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.
    Wang LZ; Sun LR; Zhao YX; Wang LL
    Int Immunopharmacol; 2011 Sep; 11(9):1211-9. PubMed ID: 21492747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.
    Hoseini SS; Cheung NV
    Cancer Lett; 2017 Jul; 399():44-52. PubMed ID: 28428075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical updates in adult acute lymphoblastic leukemia.
    Al Ustwani O; Gupta N; Bakhribah H; Griffiths E; Wang E; Wetzler M
    Crit Rev Oncol Hematol; 2016 Mar; 99():189-99. PubMed ID: 26777876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspective: assembly line immunotherapy.
    Levine BL; June CH
    Nature; 2013 Jun; 498(7455):S17. PubMed ID: 23803946
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in T-cell therapy for ALL.
    Grupp SA
    Best Pract Res Clin Haematol; 2014; 27(3-4):222-8. PubMed ID: 25455270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of cellular immunotherapy for childhood leukemia.
    Bonifant CL; Tasian SK
    Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.
    Parikh SA; Litzow MR
    Future Oncol; 2014 Nov; 10(14):2201-12. PubMed ID: 25471034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
    Yuraszeck T; Kasichayanula S; Benjamin JE
    Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
    Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
    Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.
    Epner EM; Saroya BS; Hasanali ZS; Loughran TP
    Exp Hematol; 2016 Mar; 44(3):157-60. PubMed ID: 26802532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapsed childhood acute lymphoblastic leukaemia.
    Bhojwani D; Pui CH
    Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Progress in biology and therapy of acute lymphoblastic leukemia].
    Robak T
    Postepy Hig Med Dosw; 1989; 43(2-4):291-328. PubMed ID: 2702356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
    Haining WN; Cardoso AA; Keczkemethy HL; Fleming M; Neuberg D; DeAngelo DJ; Stone RM; Galinsky I; Silverman LB; Sallan SE; Nadler LM; Guinan EC
    Exp Hematol; 2005 Mar; 33(3):286-94. PubMed ID: 15730852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.